L.I.A. Pure Capital Ltd. Files 13D for PainReform Ltd.
Ticker: PRFX · Form: SC 13D · Filed: Aug 26, 2024 · CIK: 1801834
| Field | Detail |
|---|---|
| Company | Painreform Ltd. (PRFX) |
| Form Type | SC 13D |
| Filed Date | Aug 26, 2024 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 5 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: ownership-change, schedule-13d, stake-building
Related Tickers: PRPM
TL;DR
**L.I.A. Pure Capital Ltd. just bought into PainReform Ltd. - big ownership change incoming!**
AI Summary
On August 22, 2024, L.I.A. Pure Capital Ltd. filed a Schedule 13D, indicating a change in beneficial ownership of PainReform Ltd. The filing details the acquisition of ordinary shares by L.I.A. Pure Capital Ltd., though specific dollar amounts and the exact number of shares acquired are not detailed in this excerpt. This filing signifies a potential shift in the control or influence over PainReform Ltd.
Why It Matters
This filing signals a significant change in the ownership structure of PainReform Ltd., potentially impacting its stock price and strategic direction.
Risk Assessment
Risk Level: medium — Schedule 13D filings often indicate significant stake-building, which can lead to increased volatility and potential activist investor involvement.
Key Players & Entities
- L.I.A. Pure Capital Ltd (company) — Filing person acquiring shares
- PainReform Ltd. (company) — Subject company
- August 22, 2024 (date) — Date of event requiring filing
FAQ
What is the exact number of ordinary shares of PainReform Ltd. beneficially owned by L.I.A. Pure Capital Ltd. after this filing?
The provided excerpt does not specify the exact number of shares acquired or the total percentage of beneficial ownership.
What was the date of the event that triggered this Schedule 13D filing?
The date of the event which requires filing of this statement is August 22, 2024.
Who is the subject company in this Schedule 13D filing?
The subject company is PainReform Ltd.
What is the business address of L.I.A. Pure Capital Ltd. as listed in the filing?
The business address for L.I.A. Pure Capital Ltd. is 20 Raoul Walenberg St, Tel Aviv, L3, 6971916.
What is the CUSIP number for the ordinary shares of PainReform Ltd.?
The CUSIP number for the ordinary shares of PainReform Ltd. is M77798128.
Filing Stats: 1,341 words · 5 min read · ~4 pages · Grade level 11 · Accepted 2024-08-26 08:14:39
Filing Documents
- ea0212371-13dliapure_pain.htm (SC 13D) — 57KB
- ea021237101ex99-1_pain.htm (EX-99.1) — 6KB
- 0001213900-24-072399.txt ( ) — 64KB
(b)
Item 1(b). Address of Issuer’s Principal Executive Offices: 65 Yigal Alon St., Tel Aviv 6744316 Item 2. Identity and Background (a)-(c) Pure Capital is an Israeli holding company incorporated in 2010. The address of its principal office and principal place of business is 20 Raoul Wallenberg Street, Tel Aviv, Israel 6971916, c/o Kfir Silberman. As of the date of this Schedule, Kfir Silberman, an Israeli citizen, is the officer, sole director and serves as the chairman of the board of directors of Pure Capital. Kfir Silberman is the control shareholder of Pure Capital. As of the date of this Schedule, Mr. Silberman owns 100% of the shares of Pure Capital. The address of his principal office and principal place of business is 20 Raoul Wallenberg Street, Tel Aviv, Israel 6971916. (d)-(e) During the last five years, neither Pure Capital or Kfir Silberman (collectively, the “ Reporting Persons ”) (i) has been convicted in any criminal proceeding (excluding traffic violations or similar misdemeanors) or (ii) has been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction resulting in a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws, or finding any violation with respect to such laws. (f) Kfir Silberman is an Israeli citizen. The Reporting Persons have entered into a Joint Filing Agreement, dated as of August 26, 2024, a copy of which is attached hereto as Exhibit 1. Item 3. Source and Amount of Funds or Other Consideration The Ordinary Shares reported herein as beneficially owned by Pure Capital were acquired with the working capital of Pure Capital as applicable (which may, at any given time, include margin loans made by brokerage firms in the ordinary course of business). Item 4. Purpose of Transaction. The Reporting Persons have not yet formalized any present plans or proposals that relate to o